Cargando…

Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

The identification of receptor-tyrosine kinase gene (RET) fusions in lung cancer has become crucial owing to actionable events that predict responsiveness to tyrosine kinase inhibitors (TKIs). However, RET fusions with distinct partner genes respond differently to TKIs. In this case, a 60-year-old m...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Sha-Sha, Wang, Fang, Zeng, Zhen, Gao, Fang, Liu, Huan-Huan, Wang, Hui-Na, Hu, Yi, Qin, Hai-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548572/
https://www.ncbi.nlm.nih.gov/pubmed/36226049
http://dx.doi.org/10.3389/fonc.2022.929763
_version_ 1784805459567312896
author Wang, Sha-Sha
Wang, Fang
Zeng, Zhen
Gao, Fang
Liu, Huan-Huan
Wang, Hui-Na
Hu, Yi
Qin, Hai-Feng
author_facet Wang, Sha-Sha
Wang, Fang
Zeng, Zhen
Gao, Fang
Liu, Huan-Huan
Wang, Hui-Na
Hu, Yi
Qin, Hai-Feng
author_sort Wang, Sha-Sha
collection PubMed
description The identification of receptor-tyrosine kinase gene (RET) fusions in lung cancer has become crucial owing to actionable events that predict responsiveness to tyrosine kinase inhibitors (TKIs). However, RET fusions with distinct partner genes respond differently to TKIs. In this case, a 60-year-old man was diagnosed with advanced lung adenocarcinoma. A novel RET-MIR4299/MIR8070 fusion and RET amplification were identified using next-generation sequencing (NGS). The patient was then administered with pralsetinib. After 3 weeks of therapy, the patient had a partial response. At the time of reporting, the patient was on continuous pralsetinib. These findings broaden the range of RET fusion types and provide the basis for the hypothesis that RET intergenic fusion and amplification respond to pralsetinib treatment in lung adenocarcinoma.
format Online
Article
Text
id pubmed-9548572
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95485722022-10-11 Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient Wang, Sha-Sha Wang, Fang Zeng, Zhen Gao, Fang Liu, Huan-Huan Wang, Hui-Na Hu, Yi Qin, Hai-Feng Front Oncol Oncology The identification of receptor-tyrosine kinase gene (RET) fusions in lung cancer has become crucial owing to actionable events that predict responsiveness to tyrosine kinase inhibitors (TKIs). However, RET fusions with distinct partner genes respond differently to TKIs. In this case, a 60-year-old man was diagnosed with advanced lung adenocarcinoma. A novel RET-MIR4299/MIR8070 fusion and RET amplification were identified using next-generation sequencing (NGS). The patient was then administered with pralsetinib. After 3 weeks of therapy, the patient had a partial response. At the time of reporting, the patient was on continuous pralsetinib. These findings broaden the range of RET fusion types and provide the basis for the hypothesis that RET intergenic fusion and amplification respond to pralsetinib treatment in lung adenocarcinoma. Frontiers Media S.A. 2022-09-26 /pmc/articles/PMC9548572/ /pubmed/36226049 http://dx.doi.org/10.3389/fonc.2022.929763 Text en Copyright © 2022 Wang, Wang, Zeng, Gao, Liu, Wang, Hu and Qin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Sha-Sha
Wang, Fang
Zeng, Zhen
Gao, Fang
Liu, Huan-Huan
Wang, Hui-Na
Hu, Yi
Qin, Hai-Feng
Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
title Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
title_full Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
title_fullStr Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
title_full_unstemmed Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
title_short Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
title_sort case report: a novel intergenic mir4299/mir8070-ret fusion with ret amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548572/
https://www.ncbi.nlm.nih.gov/pubmed/36226049
http://dx.doi.org/10.3389/fonc.2022.929763
work_keys_str_mv AT wangshasha casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient
AT wangfang casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient
AT zengzhen casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient
AT gaofang casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient
AT liuhuanhuan casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient
AT wanghuina casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient
AT huyi casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient
AT qinhaifeng casereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient